Novartis exec Handan He heads to Ascletis

8 October 2019
ascletis_large

Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ (NOVN: VX) pharma unit to join Ascletis (1672: HK) as chief scientific officer.

Ascletis is a Chinese biotech company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases with two products currently on the market.

Dr He’s experience with Novartis saw her manage scientific teams across global sites in the USA and Switzerland. She worked for the Swiss pharma giant for 22 years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology